Patents by Inventor Ian Mangion

Ian Mangion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10167298
    Abstract: The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: January 1, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael McNevin, Yong Liu, Ian Mangion, Alfred Lee, Joyce Stellabott, Benjamin D. Sherry, Gary Martin, Kung-I Feng, Scott Schultz, Ryan Cohen, Yanfeng Zhang
  • Patent number: 9725464
    Abstract: The present invention is directed to a process for preparing Tetracyclic Heterocycle Compounds of formula (I): which are useful as HCV NS5A inhibitors. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: August 8, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ian Mangion, Cheng-yi Chen, Ingyu Jeon, Yonggang Chen, Hongmei Li, Hoa N. Nguyen, Peter E. Maligres, Artis Klapars, Ilia Zavialov, Nobuyoshi Yasuda
  • Patent number: 9663490
    Abstract: The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase, HIV replication and the treatment of human immunodeficiency virus infection in humans.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: May 30, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tetsuji Itoh, Ingyu Jeon, Ian Mangion, Gang Qian, Benjamin D. Sherry, Donald R. Gauthier, Yang Cao
  • Publication number: 20160311834
    Abstract: The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.
    Type: Application
    Filed: October 24, 2014
    Publication date: October 27, 2016
    Inventors: Michael McNEVIN, Yong LIU, Ian MANGION, Alfred LEE, Joyce STELLABOTT, Benjamin D. SHERRY, Gary MARTIN, Kung-I FENG, Scott SHULTZ, Ryan COHEN, Yanfeng ZHANG
  • Patent number: 9441254
    Abstract: The present invention is directed to processes for preparing an intermediate for a diazepane compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: September 13, 2016
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Fred Fleitz, Ian Mangion, Jingjun Yin
  • Publication number: 20160257698
    Abstract: The present invention is directed to a process for preparing Tetracyclic Heterocycle Compounds of formula (I): which are useful as HCV NS5A inhibitors. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
    Type: Application
    Filed: October 24, 2014
    Publication date: September 8, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Ian Mangion, Cheng-yi Chen, Ingyu Jeon, Yonggang Chen, Hongmei Li, Hoa N. Nguyen, Peter E. Maligres, Artis Klapars, Ilia Zavialov, Nobuyoshi Yasuda
  • Publication number: 20150329521
    Abstract: The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase, HIV replication and the treatment of human immunodeficiency virus infection in humans.
    Type: Application
    Filed: December 4, 2013
    Publication date: November 19, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Tetsuji Itoh, Ingyu Jeon, Ian Mangion, Gang QIAN, Benjamin D. Sherry, Donald R. Gauthier, Yang CAO
  • Publication number: 20150284753
    Abstract: The present invention is directed to processes for preparing an intermediate for a diazepane compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
    Type: Application
    Filed: May 6, 2013
    Publication date: October 8, 2015
    Inventors: Fred Fleitz, Ian Mangion, Jingjun Yin
  • Publication number: 20130274475
    Abstract: Substituted bicyclic beta-lactams of Formula I: are ?-lactamase inhibitors, wherein a, X, R1 and R2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with ?-lactam antibiotics. In particular, the compounds can be employed with a ?-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to ?-lactam antibiotics due to the presence of the ?-lactamases.
    Type: Application
    Filed: June 6, 2013
    Publication date: October 17, 2013
    Inventors: Ian MANGION, Nelo Rivera, Rebecca T. Ruck, Michael Shelvin
  • Patent number: 8487093
    Abstract: Substituted bicyclic beta-lactams of Formula I: (I), are ?-lactamase inhibitors, wherein a, X, R1 and R2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with ?-lactam antibiotics. In particular, the compounds can be employed with a ?-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to ?-lactam antibiotics due to the presence of the ?-lactamases.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: July 16, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Timothy A. Blizzard, Helen Chen, Candido Gude, Jeffrey D. Hermes, Jason Imbriglio, Seongkon Kim, Jane Y. Wu, Christopher J. Mortko, Ian Mangion, Nelo Rivera, Rebecca T. Ruck, Michael Shevlin
  • Publication number: 20120053350
    Abstract: A process for the preparation of alkyl esters of N-protected oxo-azacycloalkylcarboxylic acids of Formula III: comprises contacting a ketosulfoxonium ylide of Formula II: with an iridium catalyst to obtain Compound III, wherein PG1 is an amine protective group; k is 0, 1, or 2; and RU, R1, R2, and R3 are defined herein. An embodiment of the process further com rises contacting a compound of Formula I: with a sulfoxonium halide of formula (RU)3S(O)Z, wherein Z is halide, in the presence of a strong base to obtain Compound II. Additional embodiments add a series of process steps leading to the synthesis of 7-oxo-1,6-diazabicyclo[3.2.1]octanes suitable for use as ?-lactamase inhibitors.
    Type: Application
    Filed: April 26, 2010
    Publication date: March 1, 2012
    Inventors: Ian Mangion, Mark A. Huffman, Rebecca T. Ruck, Joseph Lynch, John Y.L. Chung, Benjamin Marcune
  • Publication number: 20110294777
    Abstract: Substituted bicyclic beta-lactams of Formula I: (I), are ?-lactamase inhibitors, wherein a, X, R1 and R2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with ?-lactam antibiotics. In particular, the compounds can be employed with a ?-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to ?-lactam antibiotics due to the presence of the ?-lactamases.
    Type: Application
    Filed: January 15, 2009
    Publication date: December 1, 2011
    Inventors: Timothy A. Blizzard, Helen Chen, Candido Gude, Jeffrey D. Hermes, Jason Imbriglio, Seongkon Kim, Jane Y. Wu, Sookhee Ha, Christopher J. Mortko, Ian Mangion, Nelo Rivera, Rebecca T. Ruck, Michael Shevlin